C12N 2501/185
Osteoprotegerin
Official title: Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)
C12N2501/185 (Osteoprotegerin) appears on 7 US grants and 17 published applications in this corpus.
Search patents in C12N- Granted patents
- 7
- Published applications
- 17
- Assignees
- 14
- Inventors
- 30
- Latest grant
- 4 Aug 2020
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 3 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 1 | 2 |
| 2008 | 0 | 1 |
| 2009 | 1 | 2 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 2 | 1 |
| 2013 | 1 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 1 | 2 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
By publication year.
Recent patents
- Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells4 Aug 2020US 10,731,128 B2Alloplex Biotherapeutics, Inc.
- Generation of mature myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+progenitors30 Sep 2014US 8,846,395 B2Wisconsin Alumni Research Foundation
- Cryoconserved mature dendritic cells5 Nov 2013US 8,574,901 B2Argos Therapeutics, Inc.
- Method for producing ready to use, antigen-loaded or unloaded, cryoconserved mature dendritic cells7 Aug 2012US 8,236,562 B2Argos Therapeutics, Inc.
- Method for immunotherapy of tumors28 Feb 2012US 8,124,067 B2IMBA-Institute Fur Molekulre Biotechnologie GmbH
- Preventive and/or therapeutic agent for pressure ulcer18 Jul 2024US 2024/0238345 A1Cysay Inc.
- Nanoparticulate mineralized collagen glycosaminoglycan scaffold with an anti-resorption factor25 Feb 2021US 2021/0052771 A1The Regents of the University of California
- Biomaterial comprising adipose-derived stem cells and method for producing the same27 Aug 2020US 2020/0268939 A1Novadip Biosciences
- Compositions and methods for in vitro activation and expansion of serial killer t cell populations and passive immunization of a cancer patient with tumor cell killing cells2 Apr 2020US 2020/0102538 A1Alloplex Biotherapeutics, Inc.
- Cryoconserved Mature Dendritic Cells29 Nov 2012US 2012/0301959 A1Argos Therapeutics, Inc.
Most cited
By later US patents
- Method for producing ready to use, antigen-loaded or unloaded, cryoconserved mature dendritic cells8US 8,236,562 B2Argos Therapeutics, Inc. · 2012
- Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells6US 10,731,128 B2Alloplex Biotherapeutics, Inc. · 2020
- Cryoconserved mature dendritic cells3US 8,574,901 B2Argos Therapeutics, Inc. · 2013
- Generation of mature myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+progenitors3US 8,846,395 B2Wisconsin Alumni Research Foundation · 2014
- Method for immunotherapy of tumors2US 8,124,067 B2IMBA-Institute Fur Molekulre Biotechnologie GmbH · 2012